Advisory Services Network’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.33M | Buy |
5,218
+209
| +4% | +$97.5K | 0.03% | 588 |
|
|
2025
Q4 | $2.27M | Buy |
5,009
+162
| +3% | +$69.8K | 0.03% | 564 |
|
|
2025
Q3 | $1.9M | Sell |
4,847
-1,275
| -21% | -$533K | 0.03% | 607 |
|
|
2025
Q2 | $2.8M | Buy |
6,122
+409
| +7% | +$188K | 0.05% | 441 |
|
|
2025
Q1 | $2.77M | Sell |
5,713
-1,083
| -16% | -$505K | 0.05% | 406 |
|
|
2024
Q4 | $2.74M | Sell |
6,796
-774
| -10% | -$359K | 0.05% | 404 |
|
|
2024
Q3 | $3.55M | Hold |
7,570
| – | – | 0.07% | 296 |
|
|
2024
Q2 | $3.55M | Sell |
7,570
-2,181
| -22% | -$947K | 0.07% | 296 |
|
|
2024
Q1 | $4.08M | Buy |
9,751
+2,348
| +32% | +$993K | 0.09% | 254 |
|
|
2023
Q4 | $3.01M | Buy |
7,403
+996
| +16% | +$368K | 0.07% | 303 |
|
|
2023
Q3 | $2.23M | Sell |
6,407
-548
| -8% | -$192K | 0.06% | 380 |
|
|
2023
Q2 | $2.45M | Sell |
6,955
-396
| -5% | -$133K | 0.07% | 346 |
|
|
2023
Q1 | $2.32M | Buy |
7,351
+1,960
| +36% | +$588K | 0.06% | 355 |
|
|
2022
Q4 | $1.56M | Sell |
5,391
-192
| -3% | -$58.5K | 0.05% | 461 |
|
|
2022
Q3 | $1.62M | Buy |
5,583
+1,143
| +26% | +$329K | 0.06% | 389 |
|
|
2022
Q2 | $1.25M | Buy |
4,440
+165
| +4% | +$44.2K | 0.04% | 495 |
|
|
2022
Q1 | $1.12M | Buy |
4,275
+2,366
| +124% | +$562K | 0.03% | 597 |
|
|
2021
Q4 | $419K | Sell |
1,909
-793
| -29% | -$154K | 0.01% | 954 |
|
|
2021
Q3 | $490K | Sell |
2,702
-968
| -26% | -$189K | 0.02% | 884 |
|
|
2021
Q2 | $740K | Buy |
3,670
+736
| +25% | +$154K | 0.02% | 714 |
|
|
2021
Q1 | $632K | Buy |
2,934
+852
| +41% | +$187K | 0.02% | 745 |
|
|
2020
Q4 | $492K | Sell |
2,082
-5,160
| -71% | -$1.18M | 0.02% | 747 |
|
|
2020
Q3 | $1.97M | Sell |
7,242
-3,271
| -31% | -$902K | 0.09% | 253 |
|
|
2020
Q2 | $3.05M | Buy |
10,513
+1,006
| +11% | +$273K | 0.17% | 156 |
|
|
2020
Q1 | $2.26M | Buy |
9,507
+129
| +1% | +$29.6K | 0.15% | 173 |
|
|
2019
Q4 | $2.05M | Buy |
9,378
+4,878
| +108% | +$987K | 0.11% | 230 |
|
|
2019
Q3 | $826K | Hold |
4,500
| – | – | 0.05% | 431 |
|
|
2019
Q2 | $826K | Sell |
4,500
-1,962
| -30% | -$343K | 0.05% | 430 |
|
|
2019
Q1 | $1.19M | Sell |
6,462
-529
| -8% | -$97.7K | 0.08% | 315 |
|
|
2018
Q4 | $1.16M | Buy |
6,991
+904
| +15% | +$157K | 0.1% | 276 |
|
|
2018
Q3 | $1.17M | Buy |
6,087
+51
| +0.8% | +$9.08K | 0.09% | 309 |
|
|
2018
Q2 | $1.06M | Buy |
6,036
+1,383
| +30% | +$214K | 0.08% | 333 |
|
|
2018
Q1 | $758K | Buy |
4,653
+3,861
| +488% | +$631K | 0.06% | 405 |
|
|
2017
Q4 | $119K | Buy |
792
+611
| +338% | +$90.5K | 0.01% | 932 |
|
|
2017
Q3 | $28K | Sell |
181
-2,528
| -93% | -$381K | ﹤0.01% | 1303 |
|
|
2017
Q2 | $349K | Buy |
2,709
+2,637
| +3,663% | +$317K | 0.05% | 468 |
|
|
2017
Q1 | $8K | Buy |
+72
| New | +$6.34K | ﹤0.01% | 1569 |
|
|
2016
Q3 | $5K | Sell |
63
-53
| -46% | -$5.01K | ﹤0.01% | 1548 |
|
|
2016
Q2 | $10K | Buy |
116
+53
| +84% | +$4.58K | ﹤0.01% | 1213 |
|
|
2016
Q1 | $5K | Sell |
63
-70
| -53% | -$6.33K | ﹤0.01% | 1284 |
|
|
2015
Q4 | $17K | Buy |
133
+47
| +55% | +$5.67K | 0.01% | 835 |
|
|
2015
Q3 | $9K | Sell |
86
-106
| -55% | -$13.6K | ﹤0.01% | 957 |
|
|
2015
Q2 | $24K | Buy |
192
+8
| +4% | +$1.01K | 0.01% | 685 |
|
|
2015
Q1 | $22K | Buy |
184
+25
| +16% | +$3K | 0.01% | 664 |
|
|
2014
Q4 | $20K | Buy |
+159
| New | +$17.9K | 0.01% | 591 |
|
|
2014
Q1 | – | Sell |
-23
| Closed | -$2K | – | 788 |
|
|
2013
Q4 | $2K | Buy |
+23
| New | +$1.6K | ﹤0.01% | 1012 |
|
Other funds holding VRTX
VCM
VPM
Advisory Services Network's VRTX Position: Q1 2026 in Review
Advisory Services Network increased its Vertex Pharmaceuticals (VRTX) stake by 4.2% in Q1 2026, buying an estimated $97.5K and bringing the position to 5,218 shares worth $2.33M. The position accounts for 0.03% of the portfolio, ranked #588.
Advisory Services Network first reported a position in VRTX in Q4 2013 and has held it in 46 quarters since. The position peaked at $4.08M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Advisory Services Network held 5,218 shares of Vertex Pharmaceuticals worth $2.33M as of Q1 2026.
- Advisory Services Network bought 209 Vertex Pharmaceuticals shares in Q1 2026, an estimated $97.5K.
- Vertex Pharmaceuticals made up 0.03% of Advisory Services Network's portfolio in Q1 2026, its #588 holding.
- Advisory Services Network first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 46 quarters since.
- Advisory Services Network's Vertex Pharmaceuticals position peaked at $4.08M in Q1 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.